▎ WuXi AppTec content team editor

Hepatocellular carcinoma is the sixth most common type of cancer worldwide, with more than 900,000 new cases in 2020, and more than two-thirds of patients are already in advanced stages of the disease at the time of diagnosis, with only 7% of advanced patients surviving for more than 5 years

Carellizumab/apatinib reduces risk of disease progression or death by 48%

In this randomized, open-label, international Phase 3 clinical trial, patients with unresectable hepatocellular carcinoma were randomized to receive carellizumab/apatinib or sorafenib

The conference summary showed that the median follow-up time was 7.

In addition, at a median follow-up time of 14.

Efficacy results of carellizumab/apatinib (C+R) (Image source: Reference[2])

The researchers said this result showed that the carrelizumab/apatinib combination significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma compared with the active control

Terelizumab shows clinically significant overall survival benefit

In a randomized, open-label, phase 3 global clinical trial called RATIONALE-301, patients with unresectable hepatocellular carcinoma were treated

The conference summary showed that the median OS of the terelitizumab group was 15.
9 months at least 33 months of follow-up, and the non-inferiority criterion (HR: 0.
85) was met compared with the control group (14.
1 months).


The objective response rate of Terelizumab was 14.
3%, which was better than that of the active control group (5.
4%)
.

The median duration of remission was 36.
1 months in the terelitizumab group and 11.
0 months
in the control group.

In terms of safety, the proportion of adverse events exceeding grade 3 in the tirelizumab group and the adverse events leading to treatment discontinuation were lower than in the active control group
.

The researchers said this result shows that terelizumab, as a monotherapy, can provide clinically significant overall survival benefits and has better safety profiles
.

More innovative therapies are expected to achieve positive clinical results and bring more treatment options to liver cancer patients
.

WuXi AppTec provides integrated, end-to-end new drug development and production services to the global biopharmaceutical industry, covering chemical drug development and production, biological research, preclinical and clinical trial development, cell and gene therapy research and development, testing and production
.

If you have relevant business needs, please click on the image below to fill in the specific information
.

▲If you have any business needs, please long press to scan the QR code above, or